Exeltis Unveils Innovative Contraceptive Kelzy, Designed for Mexican Women

Mexican pharmaceutical company Exeltis, a subsidiary of CHEMO, has solidified its position as one of the most innovative players in contraception and women's health. The company strongly supports this stance with an extensive continuous medical education program that trains over 40,000 doctors annually through the GinExeltis platform, offering scientific updates and clinical materials. In an exclusive interview with LaSalud.mx, Exeltis México's General Manager, Raoul Schocher, shared the company's vision, challenges, and advancements in its commitment to providing safe, effective, and tailored solutions for the specific needs of Mexican women. One of the pillars of this approach is the treatment of Polycystic Ovary Syndrome (PCOS) through innovative formulas like Inofolic. However, it is in the field of contraception that Exeltis has made breakthroughs, presenting two global innovations after more than 25 years without significant changes in this area: Slinda and Kelzy. Slinda, an estrogen-free contraceptive, was designed for women with cardiovascular risk factors. Kelzy, the most recent launch, represents a radical innovation in combined methods thanks to its prolonged-release technology. This technology reduces hormonal fluctuations, decreases side effects, and allows for stable and predictable bleeding control. Kelzy also offers additional benefits in reducing acne, hirsutism, and other manifestations of androgen excess. Schocher acknowledges the regulatory challenges of innovating in Mexico but also highlights recent progress: «COFEPRIS has accelerated the approval of products with solid evidence». Kelzy obtained one of the broadest approvals in contraception, demonstrating confidence in its safety and efficacy profile. «In Mexico, women seek controlled, brief, and light bleeding as a sign of trust in their method,» Schocher explains. The company adapts its strategies to local cultural and medical expectations. Kelzy is initially launched in the private sector, with plans to expand to the public sector in the future. With a product launch roadmap projected until 2030, Exeltis plans to introduce 15 to 18 new products in women's health. Schocher's vision is clear: «We want any need of the Mexican woman to have a response».